Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Beigene Ltd ADR (BGNE)

Beigene Ltd ADR (BGNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,204,512
  • Shares Outstanding, K 97,476
  • Annual Sales, $ 2,459 M
  • Annual Income, $ -881,710 K
  • EBIT $ -871 M
  • EBITDA $ -783 M
  • 60-Month Beta 0.57
  • Price/Sales 6.93
  • Price/Cash Flow N/A
  • Price/Book 4.95

Options Overview Details

View History
  • Implied Volatility 47.23% ( -0.64%)
  • Historical Volatility 48.08%
  • IV Percentile 53%
  • IV Rank 55.44%
  • IV High 61.61% on 08/05/24
  • IV Low 29.34% on 08/16/24
  • Put/Call Vol Ratio 1.74
  • Today's Volume 491
  • Volume Avg (30-Day) 76
  • Put/Call OI Ratio 1.08
  • Today's Open Interest 3,213
  • Open Int (30-Day) 3,032

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.71
  • Number of Estimates 5
  • High Estimate -0.05
  • Low Estimate -1.30
  • Prior Year -3.53
  • Growth Rate Est. (year over year) +79.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
170.99 +3.22%
on 12/19/24
216.73 -18.56%
on 12/02/24
-17.76 (-9.14%)
since 11/20/24
3-Month
170.99 +3.22%
on 12/19/24
248.16 -28.88%
on 10/04/24
-25.49 (-12.62%)
since 09/20/24
52-Week
126.97 +39.01%
on 04/19/24
248.16 -28.88%
on 10/04/24
+1.25 (+0.71%)
since 12/20/23

Most Recent Stories

More News
Insider Sale: Director at $BGNE (BGNE) Sells 916,964 Shares

BROS. ADVISORS LP BAKER, a director at $BGNE ($BGNE), sold 916,964 shares of the company on 12-09-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 9.5% of...

BGNE : 176.50 (+1.02%)
Insider Sale: Director at $BGNE (BGNE) Sells 200 Shares

Xiaodong Wang, a director at $BGNE ($BGNE), sold 200 shares of the company on 11-26-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.7% of their shares....

BGNE : 176.50 (+1.02%)
BeiGene Stock Eyes 2-Week High After EU Approves Cancer Treatment: Retail Enthusiasm Grows

The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.

BGNE : 176.50 (+1.02%)
FBT : 165.53 (+0.92%)
BIB : 51.41 (+1.80%)
QQQJ : 31.36 (+1.39%)
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
BGNE : 176.50 (+1.02%)
HCM : 14.31 (-2.05%)
ABBV : 175.58 (+2.37%)
ONC.TO : 1.19 (-9.16%)
ELVN : 22.47 (-1.75%)
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

/CNW/ -- USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers among...

ONCY : 0.8310 (-6.36%)
BGNE : 176.50 (+1.02%)
HCM : 14.31 (-2.05%)
ABBV : 175.58 (+2.37%)
ONC.TO : 1.19 (-9.16%)
ELVN : 22.47 (-1.75%)
Investors Watch Key Players in Oncology as Cancer Cases Set to Skyrocket

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – The surge in...

ONCY : 0.8310 (-6.36%)
BGNE : 176.50 (+1.02%)
EXEL : 33.29 (-1.16%)
ABBV : 175.58 (+2.37%)
ONC.TO : 1.19 (-9.16%)
AMGN : 263.38 (+0.84%)
Is Regeneron Pharmaceuticals Stock Outperforming the S&P 500?

Regeneron Pharmaceuticals has outperformed the broader S&P 500 Index over the past year, and Wall Street analysts remain bullish on the stock’s prospects.

REGN : 701.85 (-0.90%)
$SPX : 5,930.85 (+1.09%)
$SPX : 5,930.85 (+1.09%)
BGNE : 176.50 (+1.02%)
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?

The big pharma company's top drug is losing ground, but its dividend keeps rising.

CVS : 44.36 (+1.32%)
UNH : 500.13 (+2.22%)
ABT : 114.23 (+1.61%)
CI : 276.92 (+0.77%)
AZN : 65.35 (+1.41%)
BGNE : 176.50 (+1.02%)
RVNC : 3.09 (+0.65%)
ABBV : 175.58 (+2.37%)
Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

/CNW/ - BeiGene, Ltd. (Nasdaq: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, today announced it received Health Canada authorization for...

BGNE : 176.50 (+1.02%)
Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib)

/CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company is pleased to announce that the Governments of Ontario and...

BGNE : 176.50 (+1.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.

See More

Key Turning Points

3rd Resistance Point 182.02
2nd Resistance Point 180.63
1st Resistance Point 178.57
Last Price 176.50
1st Support Level 175.12
2nd Support Level 173.73
3rd Support Level 171.67

See More

52-Week High 248.16
Fibonacci 61.8% 201.86
Fibonacci 50% 187.56
Last Price 176.50
Fibonacci 38.2% 173.26
52-Week Low 126.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar